Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

In the last several years, global market of Neuromyelitis Optica Drug developed with the production growth rate about 4%. In 2015 global capacity of Neuromyelitis Optica Drug is more than 9100 K units.
North America is the largest supplier of Neuromyelitis Optica Drug, with a production market share of 59.3% and a consumption market share of 18.7%.
Europe is the second largest supplier of Neuromyelitis Optica Drug, following North America with the production market share of 25% and the consumption market share of 27%. Asia (Ex China) is another important market of Neuromyelitis Optica Drug, enjoying 31.8% sales market share.

According to this study, over the next five years the Neuromyelitis Optica Drug market will register a xx% CAGR in terms of revenue, the global market size will reach USD xx million by 2024, from USD xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Neuromyelitis Optica Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuromyelitis Optica Drug market by product type, application, key manufacturers and key regions and countries.

This study considers the Neuromyelitis Optica Drug value and volume generated from the sales of the following segments-

Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Glucocorticoids
Immunoglobulin
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Acute attack
Remission prophylactic treatment

This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Pfizer
FRESENIUS
TEVA
SANDOZ
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Neuromyelitis Optica Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Neuromyelitis Optica Drug market by identifying its various subsegments.
Focuses on the key global Neuromyelitis Optica Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Neuromyelitis Optica Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Neuromyelitis Optica Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.